Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer

International Journal of Cancer

Volumn 108, Issue 1, 2004, Pages 23-30

  Scaltriti, Maurizio ^a   Brausi, Maurizio ^b   Amorosi, Andrea ^c   Caporali, Andrea ^d   D'Arca, Domenico ^a   Astancolle, Serenella ^a   Corti, Amaldo ^a   Bettuzzi, Saverio ^d  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Nuovo Ospedale S Agostino   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

Author keywords

Clusterin (SGP 2, ApoJ); Gene expression; Immunohistochemistry; In situ hybridization; Ornithine decarboxylase (ODC); Prostate cancer

Indexed keywords

CELL MARKER; CLUSTERIN; HISTONE H3; MESSENGER RNA;

APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL CYCLE S PHASE; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STAINING; WESTERN BLOTTING;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL DIFFERENTIATION; CLUSTERIN; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR CHAPERONES; PROSTATIC NEOPLASMS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0344825135     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11496     Document Type: Article

References (36)

1. Bettuzzi S, Hiipakka RA, Gilna P, Liao ST. Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem J 1989;257:293-6.
2. Silkensen JR, Schwochau GB, Rosenberg ME. The role of clusterin in tissue injury. Biochem Cell Biol 1994:72:483-8.
3. Zoli M, Ferraguti F, Zini I, Bettuzzi S, Agnati LF. Increases in sulphated glycoprotein-2 mRNA levels in the rat brain after transient forebrain ischemia or partial mesodiencephalic hemitransection. Mol Brain Res 1993:18:163-77.
4. Bettuzzi S, Strocchi P, Marinelli M, Astancolle S, Davalli P, Corti A. Gene relaxation and aging: changes in the abundance of rat ventral prostate SGP-2 (clusterin) and ornithine decarboxylase mRNAs. FEBS Lett 1994;348:255-8.
5. Bettuzzi S, Troiano L, Davalli P, Tropea F, Ingletti MC, Grassilli E, Monti D, Corti A, Franceschi C. In vivo accumulation of sulfated glycoprotein 2 mRNA in rat thymocytes upon dexamethasone-induced cell death. Biochem Biophys Res Commun 1991:175:810-5.
6. Bettuzzi S, Astancolle S, Guidetti G, Moretti M, Tiozzo R, Corti A. Clusterin (SGP-2) gene expression is cell cycle dependent in normal human dermal fibroblasts. FEBS Lett 1999;448:297-300.
7. Grassilli E, Bettuzzi S, Monti D, Ingletti MC, Franceschi C, Corti A. Studies on the relationship between cell proliferation and cell death: opposite patterns of SGP-2 and ornithine decarboxylase mRNA accumulation in PHA-stimulated human lymphocytes. Biochem Biophys Res Commun 1991;180:59-63.
8. Bettuzzi S, Zoli M, Ferraguti F, Ingletti MC, Agnati LF, Corti A. Regional and cellular distribution within the rat prostate of two mRNA species undergoing opposite regulation by androgens. J Endocrinol 1992;132:361-7.
9. Marinelli M, Quaglino D, Bettuzzi S, Strocchi P, Davalli P, Corti A. Increased levels of clusterin mRNA in the ventral prostate of the aging rat are associated to increases in cuboidal (atrophic) cell population and not to changes in apoptotic activity. Biochem Cell Biol 1994;72: 515-21.
10. Astancolle S, Guidetti G, Pinna C, Corti A, Bettuzzi S. Increased levels of clusterin (SGP-2) mRNA and protein accompany rat ventral prostate involution following finasteride treatment. J Endocrinol 2000;167:197-204.
11. Wong P, Pfeffer BA, Bernstein SL, Chambers ML, Chader GJ, Zakeri ZF, Wu YQ, Wilson MR, Becerra SP. Clusterin protein diversity in the primate eye. Mol Vis 2000;27:6184-91.
12. Lakins J, Bennett S, Chen J, Arnold J, Morrissey C, Wong P, O'Sullivan J, Tenniswood M. Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. J Biol Chem 1998; 273:27887-95.
13. Wong P, Ulyanova T, Organisciak D-T, Bennett S, Lakins J, Arnold J-M, Kutty R-K, Tenniswood M, vanVeen T, Darrow R-M, Chader G. Expression of multiple forms of clusterin during light-induced retinal degeneration. Curr Eye Res 2001;23:157-65.
14. Koch-Brandt C, Morgans C. Clusterin: a role in cell survival in the face of apoptosis? Prog Mol Subcell Biol 1996;16:130-49.
15. Miyake H, Hara S, Zellweger T, Kamidono S, Gleave ME, Hara I. Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Mol Urol 2001;5: 105-11.
16. Miyake H, Nelson C, Rennie P, Gleave M. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000;60:2547-54.
17. Kalka K, Ahmad N, Criswell T, Boothman D, Mukhtar H. Upregulation of clusterin during phthalocyanine 4 photodynamic therapy-mediated apoptosis of tumour cells and ablation of mouse skin tumours. Cancer Res 2000;60:5984-7.
18. Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ, Kinsella TJ, Boothman DA. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci USA 2000;97:5907-12.
19. Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 2001; 58:39-49.
20. Bettuzzi S, Davalli P, Astancolle S, Carani C, Madeo B, Tampieri A, Corti A. Tumour progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 2000;60:28-34.
21. Cole G, Ard M. Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein. Microsc Res Tech 2000;50:316-24.
22. Boggs LN, Fuson KS, Baez M, Churgay L, McClure D, Becker G, May PC. Clusterin (Apo J) protects against in vitro amyloid-beta (1-40) neurotoxicity. J Neurochem 1996;67:1324-7.
23. Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech 2000;50:305-15.
24. Bartl MM, Luckenbach T, Bergner O, Ullrich O, Koch-Brandt C. Multiple receptors mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Exp Cell Res 2001;271:130-41.
25. Poon S, Treweek TM, Wilson MR, Easterbrook-Smith SB, Carver JA. Clusterin is an extracellular chaperone that specifically interacts with slowly aggregating proteins on their off-folding pathway. FEBS Lett 2002;513:259-66.
26. Ayala GE, Wheeler TM, Shine HD, Schmelz M, Frolov A, Chakraborty S, Rowley D. In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate 2001;49:213-23.
27. Purrello M, Bettuzzi S, Di Pietro C, Mirabile E, Di Blasi M, Rimini R, Grzeschik KH, Ingletti C, Corti A, Sichel G. The gene for SP-40,40, human homolog of rat sulfated glycoprotein 2. rat clusterin, and rat testosterone-repressed prostate message 2, maps to chromosome 8. Genomics 1991;10:151-6.
28. Fink TM, Zimmer M, Tschopp J, Etienne J, Jenne DE, Lichter P. Human clusterin (CLI) maps to 8p21 in proximity to the lipoprotein lipase (LPL) gene. Genomics 1993;16:526-8.
29. Latil A, Baron JC, Cussenot O, Fournier G, Soussi T, Boccon Gibod L, Le Duc A, Rouesse J, Lidereau R. Genetic alterations in localized prostate cancer: identification of a common region of deletion on chromosome arm 18q. Genes Chromosomes Cancer 1994;11:119-25.
30. Latil A, Fournier G, Cussenot O, Lidereau R. Differential chromosome allelic imbalance in the progression of human prostate cancer. J Urol 1996;156:2079-83.
31. Emmert Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995;55:2959-62.
32. Ichikawa T, Nihei N, Suzuki H, Oshimura M, Emi M, Nakamura Y, Hayata I, Isaacs JT, Shimazaki J. Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. Cancer Res 1994;54:2299-302.
33. Bettuzzi S, Scorcioni F, Astancolle S, Davalli P, Scaltriti M, Corti A. Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalised human prostate epithelial cells by slowing down cell cycle progression. Oncogene 2002;21:4328-34.
34. Zhang LY, Ying WT, Mao YS, He HZ, Liu Y, Wang HX, Liu F, Wang K, Zhang DC, Wang Y, Wu M, Qian XH, et al. Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol 2003;9:650-4.
35. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002;50:179-88.
36. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, Kozlowski JM, Sensibar JA. Intracellular levels of SGP-2 (clusterin) correlate with tumour grade in prostate cancer. Clin Cancer Res 1997;3:1707-11.